CIPLA LIMITED

• Cipla has introduced ZEMDRI (Plazomicin), a novel intravenous aminoglycoside treatment for complicated urinary tract infections (cUTI) including pyelonephritis in adult patients in India. • The drug demonstrates promising activity against multi-drug resistant bacteria, including Carbapenem-resistant Enterobacteriaceae (CRE), addressing a critical challenge in managing resistant infections in India. • ZEMDRI's approval was supported by the EPIC clinical trial, the first randomized controlled study of once-daily aminoglycoside therapy for cUTI treatment, with Cipla generating India-specific pathogen data to validate its effectiveness.

Cipla's Goa API facility and Sitec Labs' Mahape analytical testing facility have both received Voluntary Action Indicated (VAI) status from the USFDA following recent inspections.

Pulmatrix plans to divest its clinical assets including PUR3100, a Phase 2-ready inhaled treatment for acute migraine, as part of its upcoming merger with Cullgen expected to close in June 2025.

Cipla projects EBITDA margins of 23.5-24.5% for FY26 while targeting growth through GLP-1 therapies, particularly semaglutide generics launching globally as patents expire.

Cipla has received CDSCO panel approval to proceed with Phase III clinical trials for inhaled itraconazole dry powder (PUR1900) at a 40mg dose, following successful Phase II results.

Cipla has secured USFDA approval for paclitaxel protein-bound particles for injectable suspension, a generic version of Bristol Myers Squibb's Abraxane, indicated for treating multiple cancer types.

Formosa Pharmaceuticals has granted Cipla Limited exclusive rights to market clobetasol propionate ophthalmic suspension 0.05% (APP13007) across 11 countries in Asia, Africa, and South America.

Danish pharmaceutical giant Novo Nordisk confirms readiness to launch its blockbuster GLP-1 drug Semaglutide (Ozempic) in India despite patent expiration in January 2026, emphasizing continued market leadership strategy.

Mankind Pharma has developed a pioneering GPR109 agonist as the world's first potential small-molecule oral treatment for obesity, currently advancing through Phase 2 trials in Australia.

Cipla's stock price has increased by approximately 11% over three trading sessions following the US FDA's clearance of its Goa manufacturing facility.